MA52492B1 - Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés - Google Patents
Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associésInfo
- Publication number
- MA52492B1 MA52492B1 MA52492A MA52492A MA52492B1 MA 52492 B1 MA52492 B1 MA 52492B1 MA 52492 A MA52492 A MA 52492A MA 52492 A MA52492 A MA 52492A MA 52492 B1 MA52492 B1 MA 52492B1
- Authority
- MA
- Morocco
- Prior art keywords
- rip1
- preparation
- methods
- kinase
- inhibitory compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title abstract 2
- 102100021009 Cytochrome b-c1 complex subunit Rieske, mitochondrial Human genes 0.000 title 1
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 title 1
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102100021559 KRR1 small subunit processome component homolog Human genes 0.000 abstract 3
- 101150040948 RIP1 gene Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Abstract
L'invention concerne des composés inhibiteurs de kinase, tels que des composés inhibiteurs de protéine kinase 1 interagissant avec le récepteur (rip1), ainsi que des compositions pharmaceutiques et des combinaisons comprenant de tels composés inhibiteurs. Les composés selon l'invention, les compositions pharmaceutiques et/ou les combinaisons peuvent être utilisés pour inhiber une kinase rip1 in vivo ou ex vivo, et peuvent également traiter ou prévenir une maladie ou un état pathologique associé à une kinase, en particulier une maladie ou un état pathologique associé à rip1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862666452P | 2018-05-03 | 2018-05-03 | |
PCT/US2019/030473 WO2019213445A1 (fr) | 2018-05-03 | 2019-05-02 | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés |
Publications (2)
Publication Number | Publication Date |
---|---|
MA52492A MA52492A (fr) | 2021-03-10 |
MA52492B1 true MA52492B1 (fr) | 2023-09-27 |
Family
ID=66554488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA52492A MA52492B1 (fr) | 2018-05-03 | 2019-05-02 | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés |
Country Status (35)
Country | Link |
---|---|
US (2) | US10975064B2 (fr) |
EP (1) | EP3788045B1 (fr) |
JP (1) | JP7379467B2 (fr) |
KR (1) | KR20210006407A (fr) |
CN (1) | CN112384510A (fr) |
AU (1) | AU2019262142A1 (fr) |
BR (1) | BR112020022423A2 (fr) |
CA (1) | CA3099018A1 (fr) |
CL (1) | CL2020002840A1 (fr) |
CO (1) | CO2020015153A2 (fr) |
CR (1) | CR20200582A (fr) |
CY (1) | CY1126152T1 (fr) |
DK (1) | DK3788045T3 (fr) |
DO (1) | DOP2020000197A (fr) |
EA (1) | EA202092581A1 (fr) |
EC (1) | ECSP20077518A (fr) |
ES (1) | ES2947446T3 (fr) |
FI (1) | FI3788045T3 (fr) |
HR (1) | HRP20230909T1 (fr) |
HU (1) | HUE062277T2 (fr) |
IL (1) | IL278416B2 (fr) |
JO (1) | JOP20200277A1 (fr) |
LT (1) | LT3788045T (fr) |
MA (1) | MA52492B1 (fr) |
MD (1) | MD3788045T2 (fr) |
MX (1) | MX2020011622A (fr) |
PE (1) | PE20210414A1 (fr) |
PH (1) | PH12020551848A1 (fr) |
PL (1) | PL3788045T3 (fr) |
PT (1) | PT3788045T (fr) |
RS (1) | RS64418B1 (fr) |
SG (1) | SG11202010913PA (fr) |
SI (1) | SI3788045T1 (fr) |
WO (1) | WO2019213445A1 (fr) |
ZA (1) | ZA202007487B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20200582A (es) | 2018-05-03 | 2021-04-14 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos |
SI3788044T1 (sl) | 2018-05-03 | 2023-12-29 | Rigel Pharmaceuticals, Inc. | Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo |
TW202122397A (zh) | 2019-09-06 | 2021-06-16 | 美商雷傑製藥公司 | Rip1抑制性化合物及用於製備和使用其之方法 |
KR20220042429A (ko) | 2019-09-06 | 2022-04-05 | 리겔 파마슈티칼스, 인크. | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 |
US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
US11753381B2 (en) | 2019-09-27 | 2023-09-12 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
CN115298184A (zh) * | 2019-11-07 | 2022-11-04 | 里格尔药品股份有限公司 | 杂环rip1抑制化合物 |
EP4065565A4 (fr) * | 2019-11-26 | 2023-12-06 | Board of Regents, The University of Texas System | Inhibiteurs de la protéine kinase 1 interagissant avec les récepteurs pour le traitement d'une maladie |
AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
CN115867557A (zh) * | 2021-05-14 | 2023-03-28 | 中国医药研究开发中心有限公司 | 氮杂卓类稠环化合物及其医药用途 |
CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
WO2023076133A1 (fr) * | 2021-10-27 | 2023-05-04 | Merck Sharp & Dohme Llc | Inhibiteurs de ripk1 spirotricycliques et leurs procédés d'utilisation |
KR20230100646A (ko) * | 2021-12-24 | 2023-07-05 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
CA2031376A1 (fr) | 1989-12-04 | 1991-06-05 | Bahram Farhadieh | Dispositif transdermique monocouche pour l'administration de medicaments |
US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
CA2123809A1 (fr) | 1991-12-18 | 1993-06-24 | Debra L. Wilfong | Pellicule d'etancheite multicouche |
ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
JP5645663B2 (ja) | 2007-08-15 | 2014-12-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ネクロトーシスのヘテロ環式抑制剤 |
TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 (二) |
US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
CN106573006A (zh) * | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
CN107207485A (zh) | 2015-02-13 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | (S)‑5‑苄基‑N‑(5‑甲基‑4‑氧代‑2,3,4,5‑四氢苯并[b][1,4]氧氮杂环庚三烯‑3‑基)‑4H‑1,2,4‑***‑3‑甲酰胺的晶型 |
MX2017016482A (es) * | 2015-07-02 | 2018-03-08 | Hoffmann La Roche | Lactamas biciclicas y metodos de uso de las mismas. |
US10426758B2 (en) | 2015-10-13 | 2019-10-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
JP6754772B2 (ja) | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
CR20180413A (es) * | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
EP3526219B1 (fr) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Lactames de pyridone bicycliques et leurs méthodes d'utilisation |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
CA3052767A1 (fr) | 2017-02-27 | 2018-08-30 | Glaxosmithkline Intellectual Property Development Limited | Amides heterocycliques en tant qu'inhibiteurs de kinase |
SI3788044T1 (sl) | 2018-05-03 | 2023-12-29 | Rigel Pharmaceuticals, Inc. | Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo |
CR20200582A (es) | 2018-05-03 | 2021-04-14 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos |
US20210292340A1 (en) | 2018-06-26 | 2021-09-23 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Cell necrosis inhibitor, preparation method therefor and use thereof |
WO2020088194A1 (fr) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | Amide hétérocyclique inhibant la kinase rip1 et ses applications |
TW202122397A (zh) | 2019-09-06 | 2021-06-16 | 美商雷傑製藥公司 | Rip1抑制性化合物及用於製備和使用其之方法 |
KR20220042429A (ko) | 2019-09-06 | 2022-04-05 | 리겔 파마슈티칼스, 인크. | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 |
AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2019
- 2019-05-02 CR CR20200582A patent/CR20200582A/es unknown
- 2019-05-02 MA MA52492A patent/MA52492B1/fr unknown
- 2019-05-02 EA EA202092581A patent/EA202092581A1/ru unknown
- 2019-05-02 HU HUE19724662A patent/HUE062277T2/hu unknown
- 2019-05-02 IL IL278416A patent/IL278416B2/en unknown
- 2019-05-02 RS RS20230648A patent/RS64418B1/sr unknown
- 2019-05-02 SI SI201930550T patent/SI3788045T1/sl unknown
- 2019-05-02 CA CA3099018A patent/CA3099018A1/fr active Pending
- 2019-05-02 US US16/402,103 patent/US10975064B2/en active Active
- 2019-05-02 PT PT197246622T patent/PT3788045T/pt unknown
- 2019-05-02 CN CN201980045150.5A patent/CN112384510A/zh active Pending
- 2019-05-02 KR KR1020207034544A patent/KR20210006407A/ko unknown
- 2019-05-02 JO JOP/2020/0277A patent/JOP20200277A1/ar unknown
- 2019-05-02 LT LTEPPCT/US2019/030473T patent/LT3788045T/lt unknown
- 2019-05-02 AU AU2019262142A patent/AU2019262142A1/en active Pending
- 2019-05-02 FI FIEP19724662.2T patent/FI3788045T3/fi active
- 2019-05-02 MD MDE20210214T patent/MD3788045T2/ro unknown
- 2019-05-02 JP JP2021510283A patent/JP7379467B2/ja active Active
- 2019-05-02 EP EP19724662.2A patent/EP3788045B1/fr active Active
- 2019-05-02 ES ES19724662T patent/ES2947446T3/es active Active
- 2019-05-02 DK DK19724662.2T patent/DK3788045T3/da active
- 2019-05-02 BR BR112020022423-5A patent/BR112020022423A2/pt unknown
- 2019-05-02 WO PCT/US2019/030473 patent/WO2019213445A1/fr active Application Filing
- 2019-05-02 SG SG11202010913PA patent/SG11202010913PA/en unknown
- 2019-05-02 PL PL19724662.2T patent/PL3788045T3/pl unknown
- 2019-05-02 MX MX2020011622A patent/MX2020011622A/es unknown
- 2019-05-02 PE PE2020001796A patent/PE20210414A1/es unknown
- 2019-05-02 HR HRP20230909TT patent/HRP20230909T1/hr unknown
-
2020
- 2020-11-02 CL CL2020002840A patent/CL2020002840A1/es unknown
- 2020-11-02 DO DO2020000197A patent/DOP2020000197A/es unknown
- 2020-11-03 PH PH12020551848A patent/PH12020551848A1/en unknown
- 2020-12-01 ZA ZA2020/07487A patent/ZA202007487B/en unknown
- 2020-12-01 CO CONC2020/0015153A patent/CO2020015153A2/es unknown
- 2020-12-01 EC ECSENADI202077518A patent/ECSP20077518A/es unknown
-
2021
- 2021-03-23 US US17/210,261 patent/US11919890B2/en active Active
-
2023
- 2023-07-25 CY CY20231100349T patent/CY1126152T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
MA52488B1 (fr) | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation | |
MA41072A1 (fr) | Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline | |
MA34516B1 (fr) | Imidizopyridazines substituees | |
MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
MA40814A1 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA41932B1 (fr) | Méthodes de traitement ou de prévention de migraines | |
MA29723B1 (fr) | Composes | |
MA45811A (fr) | Méthodes et compositions de traitement de maladie. | |
MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
MA38261A1 (fr) | Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc) | |
HUP0100867A2 (hu) | Celecoxib tartalmú gyógyászati készítmények | |
MA41179A (fr) | Composés inhibiteurs de parg | |
MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
MY145074A (en) | Thiazolidin-4-one derivatives | |
MA34308B1 (fr) | Triazolopyridines substituées | |
MA46611B1 (fr) | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs | |
MA32688B1 (fr) | Composes n-sulfonamido pyrazolyles polycycliques | |
MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
FR3063645B1 (fr) | Acefapc pour le traitement des maladies acetylcholine dependantes | |
MA41174B1 (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta |